SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
US Quantum Stocks Surge After $2 Billion Government Investment 
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 
SpaceX IPO Hype Raises Questions as Many Major Stock Debuts Underperform Market 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
Lam Research Expands AI-Powered Semiconductor Tools and Arizona Operations 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
Huawei Chip Breakthrough Sparks Rally in Chinese Semiconductor Stocks 
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
Amgen (NASDAQ: AMGN) is investing $200 million in its new technology and innovation center in Hyderabad, India, to enhance AI and data-driven drug development. CEO Robert Bradway, speaking at the site's inauguration, confirmed plans for further investments in the coming years.
The Hyderabad facility, announced last year, aims to accelerate medicine development through cutting-edge technology. By year-end, it is expected to employ 2,000 people, with 300 already on board, according to Som Chattopadhyay, Amgen's national executive for India.
Amgen’s expansion aligns with India’s growing role as the “pharmacy of the world,” attracting global pharmaceutical giants. The company’s presence in Hyderabad coincides with the BioAsia conference, where key executives from Amgen, Eli Lilly (NYSE: LLY), Novartis (SIX: NOVN), and leading Indian pharma firms will participate.
The U.S. and India recently initiated talks for a trade deal to strengthen collaboration in emerging technologies. U.S. Consul General in Hyderabad, Jennifer Larson, highlighted Amgen’s expansion as a prime example of this partnership. However, potential U.S. tariffs on pharmaceutical imports—reportedly 25% or higher—could impact Indian drugmakers, as the U.S. remains their largest market.
With Amgen’s strategic investment, India’s biotech sector continues to gain global attention, reinforcing its position as a key hub for pharmaceutical innovation.
